IM Cannabis vs Pelthos Therapeutics
IM Cannabis is the larger business, with $39.2m of revenue in fiscal 2025 against $16.8m for Pelthos Therapeutics (2.3 times as much). IM Cannabis kept more of each dollar of sales as profit: a net margin of -20.7% against -257.9%.
| Latest fiscal year | IM CannabisIMCC, 2025 | Pelthos TherapeuticsPTHS, 2025 |
|---|---|---|
| Revenue | $39.2m | $16.8m |
| Revenue growth | -0.7% | — |
| Net income | −$8.1m | −$43.3m |
| Operating margin | -21.2% | -193.1% |
| Net margin | -20.7% | -257.9% |
| Return on equity | — | — |
| Free cash flow | $3.4m | −$22.7m |
| Cash | $2.0m | $18.0m |
| Total debt | $11.8m | $31.4m |
| Debt to equity | — | 80.9% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $0 |
| Employees | — | 92 |
| Market value | $4.2m | $39.1m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 2 buys, 24 sales |